Explore Stanford technologies available for licensing:

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second leading cause of cancer-related deaths in the United States by 2030.

Researchers at Stanford have developed a mammalian-cell-based directed evolution platform that combines programmable RNA editing with viral-mediated recombination to enable iterative diversification and optimization of protein and nucleic acid sequences.

Stanford researchers have developed a novel, cell-free platform for rapid and high-throughput protein function analysis. This technology harnesses hydrogel bead-based emulsification to parallelize and screen DNA-encoded protein libraries in a scalable, efficient manner.

Stanford researchers have developed Microbe-Independent Deep Assembly and Screening (MIDAS-M), a novel platform that dramatically accelerates the cloning of protein variants and its analysis in mammalian cells.

Stanford researchers have developed a targeted antisense oligonucleotide (ASO) platform to restore physiological regulation of DYRK1A, a key driver of neurodevelopmental and neurodegenerative pathology in Down syndrome (Trisomy 21) and other tauopathies.

Researchers at Stanford have created the first small primate model to study human heart rhythm disorders and also discovered a new way the heart keeps its beat.

Stanford researchers have developed a human spleen organoid platform that models inflammation and autoimmune responses to bacterial peptidoglycans in a physiologically relevant human immune setting.

Stanford researchers have identified that increased oxidative stress is a key molecular signature of fatigue-based conditions including Long COVID and myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS).

Researchers at Stanford have developed ComBind, a computational platform that improves prediction of how drug molecules bind to their protein targets by combining structural modeling with readily available binding data from other molecules.

Opioid use disorders are responsible for a huge number of deaths in the US and abroad every year.

Stanford researchers have developed a targeted antisense oligonucleotide (ASO) therapy to selectively reduce the expression of NaV1.7, a key sodium channel implicated in chronic pain signaling.

Stanford researchers have developed a new class of aryl ester RNA-reactive reagents that are stable for months in water yet rapidly modify RNA upon catalytic activation, enabling reliable, scalable tools for RNA research and therapeutic applications.

Stanford researchers have developed a general system to regulate the activities of specific proteins in mammalian cells using cell-permeable, synthetic molecules.

Stanford scientists have developed Plate-C, a high-throughput screening platform that captures genome-wide 3D chromatin architecture as a comprehensive cellular phenotype.

MANIfold is a novel method developed for systematic, high throughput measurements of nucleic acid secondary structure.